A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

Launched by AMYDIS INC. · Jan 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called AMDX-2011P, which aims to find amyloid deposits in the retina (the light-sensitive layer at the back of the eye) of people with Primary Open Angle Glaucoma (POAG). POAG is a condition that can damage the optic nerve and affects vision. The researchers want to see if this new treatment can help in identifying these deposits, which may be linked to the progression of glaucoma.

To participate in this study, you need to be diagnosed with POAG in both eyes and have some level of damage to your optic nerve as assessed by an eye doctor. You should also be able to fixate or focus your vision during tests. However, if you have trouble reading or writing, or if there are other serious eye problems (apart from cataracts), you may not be eligible. If you join the study, you can expect to undergo some eye exams and imaging tests to help the researchers gather important information about your condition. This trial is currently looking for participants of all genders, aged 80 to 35, who meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of primary open angle glaucoma in both eyes
• • 2. Able to fixate
• • 3. Glaucomatous optic nerve damage in both eyes, as determined by an investigator as part of an eye exam
• Exclusion Criteria:
• • 1. Participants unable to read or write
• • 2. Ocular media is not sufficiently clear to obtain acceptable quality images
• • 3. Participants with presence of any ocular pathology other than glaucoma in the study eye (cataracts are acceptable)